优化现代急性淋巴细胞白血病治疗:维持治疗时长在不同协作组间的差异
儿童及年轻成人急性淋巴细胞白血病(ALL)经当代多药化疗大多可治愈,生存率高主要源于国际协作组70年随机临床试验。当代ALL治疗通常为2至3年多药化疗,包括中枢神经系统预防,先用5至9个月强化疗,随后延长低强度维持期。历史上部分协作组给男孩维持治疗比女孩多1年,但儿童肿瘤协作组(COG)最新B-ALL试验已改为男女治疗时长相同。本文讨论该改变理由、各协作组实践差异及维持治疗时长观点。
要点
- 当代ALL治疗含2至3年多药化疗及中枢神经系统预防。
- 历史上部分协作组给男孩维持治疗比女孩多1年。
- 额外1年治疗增加患者家庭负担及潜在短期和长期风险。
核心结论
- 儿童肿瘤协作组(COG)在最新一代B细胞ALL试验中已改为男孩和女孩接受相同时长的治疗。
- 额外1年维持治疗给患者和家庭带来显著负担,并涉及可能危及生命和致衰的短期和长期风险。
研究设计与样本
- 本文为综述,基于国际协作组70年随机临床试验数据,讨论ALL维持治疗时长差异及理由。
主要发现
- 当代ALL治疗通常包括2至3年多药化疗,含中枢神经系统预防,先用5至9个月更密集化疗,随后延长低强度维持期。
- 历史上少数协作组给男孩维持治疗比女孩多1年,多数协作组男女治疗时长相同;该做法源于旧版低强度方案中男孩生存较差。
- 儿童肿瘤协作组(COG)最近改变做法,在当前一代B细胞ALL试验中男女治疗时长相同。
关键数值与推荐
- 当代ALL治疗通常持续2至3年,包括5至9个月更密集化疗后延长低强度维持期。
- 历史上少数协作组给男孩维持治疗比女孩多1年;多数协作组男女治疗时长相等。
临床怎么用
- 临床应关注儿童肿瘤协作组(COG)最新B细胞ALL试验中男女维持治疗时长相同的做法。
- 评估维持治疗时长时需权衡额外治疗带来的患者和家庭负担及短期和长期风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A majority of children and young adults with acute lymphoblastic leukemia (ALL) are cured with contemporary multiagent chemotherapy regimens. The high rate of survival is largely the result of 70 years of randomized clinical trials performed by international cooperative groups. Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years that includes central nervous system (CNS) prophylaxis, primarily consisting of CNS-penetrating systemic agents and intrathecal therapy. Although the treatment backbones vary among cooperative groups, the same agents are used, and the outcomes are comparable. ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase. Historically, a few cooperative groups treated boys with 1 more year of maintenance therapy than girls; however, most groups treated boys and girls with equal therapy lengths. This practice arose because of inferior survival in boys with older less-intensive regimens. The extra year of therapy added significant burden to patients and families and involved short- and long-term risks that were potentially life threatening and debilitating. The Children's Oncology Group recently changed its approach as part of its current generation of trials in B-cell ALL and now treats boys and girls with the same duration of therapy. We discuss the rationale behind this change, review the data and differences in practice across cooperative groups, and provide our perspective regarding the length of maintenance therapy.
引用
- Teachey DT, Hunger SP, Loh ML, et al. Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. Blood. 2021. PMID: 32877503. doi:10.1182/blood.2020007702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。